Researchers suggested that the 2017 classifications do not currently allow for uniform stratification and proper outcome prognostication for surgically treated patients with p16-positive oropharyngeal squamous cell carcinoma.
Treating head and neck cancer with selective neck dissection showed an improvement in shoulder function when level 2b neck dissection was omitted in treatment, according to a recent study.
Patients with head and neck cancer saw better overall survival when treated at academic comprehensive cancer programs and integrated network cancer programs, compared to comprehensive community cancer programs and community cancer programs.
This research indicated that routine HPV testing may be necessary for patients with squamous cell carcinoma.
Administering a high dose of gabapentin also increased the percentage of patients who required no opioid during treatment, indicating that patients were possibly gleaning benefits from gabapentin in both treatment arms.
These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.
The drug candidate tipifarnib (Zarnestra) is being clinically studied for the treatment of patients with HRAS-mutant head and neck squamous cell carcinoma after progression on platinum therapy.
True acupuncture resulted in fewer and less severe radiation-induced xerostomia symptoms in this phase III study.
Researchers found that there is an increasing incidence of late stage head and neck cancer in the U.S., highlighting the need for continuous public health efforts toward early detection.
Predictive models demonstrated the ability to anticipate adverse opioid-related outcomes among cancer survivors.